The heart health strain Lactobacillus reuteri NCIMB 30242 (LRC®), hereafter referred to by use of the trademark, LRC®, is one of Chr. Hansen’s top contributions to probiotic use in new health areas.
This award-winning probiotic strain for heart health is backed by intensive probiotic scientific research.
The LRC® strain has been associated with several health benefits. Some studies indicate that it may:
How Chr. Hansen identified the LRC® strain
A proprietary Chr. Hansen technology was used to narrow a selection of more than 350 strains down to one. This technology identified probiotic candidates with the potential to support better health and natural balance.
Strains were validated for bile salt hydrolase (BSH) activity, GIT viability, commercialization characteristics, and finally screened in human scientific studies.
In the end Lactobacillus reuteri NCIMB 30242 was selected for its ability to naturally help support total and cholesterol levels already within the normal range.
The LRC® probiotic strain is supported by multiple randomized, double blind, placebo-controlled human studies. A sampling of the study results can be found below:
Study in adults supporting heart health
A study completed to evaluate the support for heart health and safety of an LRC® capsule in adults with mild cholesterol issues resulted in an 11.6% reduction in cholesterol, as compared to placebo, over nine weeks.2
Study in adults supporting normal vitamin D levels
During a randomized, double-blind, placebo-controlled study, subjects receiving the LRC® strain attained a significant increase of 22.4% (as compared to placebo) in circulating 25-hydroxyvitamin D after nine weeks.3
The LRC® strain won the NEXT Innovation Summit’s NutraAward 2014 for best new ingredient, presented at Natural Products Expo West.
The LRC® probiotic strain has proven stable in a variety of delivery formats including supplements and some other foods. Its ability to withstand harsh processing means there are many application possibilities.
LRC® is a registered trademark of Chr. Hansen A/S.
References
1 Jones et al. Br J Nutr 2012.
2 Jones et al. Euro J Clin Nutr 2012.
3 Jones et al. J Clin Endocrinol Metab 2013.
4 Jones et al. Exp Opin Biol Ther 2013.
This communication is only intended for business-to-business and health care professionals. This communication is not intended for consumers of final consumer goods. Nothing on this page is meant to be perceived as an approved claim.
